New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
Tools›Compare›IGF-1 LR3 vs Selank

IGF-1 LR3 vs Selank

Side-by-side comparison of key properties, dosing, and research.

Anabolic & IGF
IGF-1 LR3
Cognitive Enhancement
Selank
Summary
IGF-1 LR3 is a synthetic analog of Insulin-like Growth Factor-1 with an extended half-life. It is one of the most potent anabolic peptides available, directly stimulating muscle cell hyperplasia and hypertrophy, and is the downstream mediator of many of GH's anabolic effects.
Selank is a synthetic heptapeptide analog of tuftsin developed in Russia. It is a potent anxiolytic that reduces anxiety and enhances cognitive function without sedation or addiction. It is approved for clinical use in Russia for anxiety disorders.
Half-Life
20–30 hours
Minutes (but effects persist for hours)
Admin Route
SubQ, IM
SubQ, Intranasal
Research
—
—
Typical Dose
40–80 mcg
250–500 mcg
Frequency
Once daily or split twice daily
1–3 times daily
Key Benefits
  • Direct muscle hypertrophy via IGF-1R stimulation
  • Muscle hyperplasia (new fiber formation) — unique among peptides
  • Rapid gains in lean muscle mass
  • Accelerated recovery from training and injury
  • Increased nutrient uptake by muscle cells
  • Fat oxidation enhancement
  • Bone density improvement
  • Cartilage and connective tissue repair
  • Reduces anxiety without sedation
  • Enhances memory and learning
  • Improves focus and concentration
  • Stabilizes mood
  • Reduces physiological stress response
  • May enhance motivation
  • No addiction potential or withdrawal
  • Fast-acting — effects within 20–30 minutes
  • Approved clinically in Russia for anxiety disorders
Side Effects
  • Hypoglycemia (significant risk — insulin-like activity)
  • Acromegaly-like effects with excessive long-term use
  • Jaw and hand swelling
  • Organ hypertrophy with extreme doses
  • +2 more
  • Mild sedation at higher doses (paradoxical)
  • Fatigue (rare)
  • Irritability during discontinuation (uncommon)
Stacks With
—
—